Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026 announced.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Corporate update accompanies the earnings release
- Exhibit 99.1 contains the detailed financial results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- KOMZIFTI revenue $13.9M, up 53% sequentially, with new patient starts up 30% and prescriptions up 65%
- Majority share of new patient starts supports commercial momentum in R/R NPM1-mutated AML
- Cash and investments $492.1M, supplemented by $55M Oberland funding and up to $300M total financing capacity
- Oberland debt carries 6.95%-8.95% interest over seven years, plus a capped single-digit U.S. KOMZIFTI royalty
- FDA-aligned approximately 40-patient darlifarnib registration study targeted for 1H 2027, creating a potential second product approval pathway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.